As banks have increasingly failed to provide products and services tailored to low-income customers, many have flocked to alternative financial service providers.
A study confirms that people who make less than $50,000 a year are 37 percent less likely to participate in clinical trials for new cancer treatments—and that's bad news for everybody involved.